TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01101321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (Totowa) (oxycodone HCl)
Description: Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reformulated OXY (Wilson) (oxycodone HCl)
Description: Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
Study: NCT00643006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Supervised walks with poles twice a week at moderate-high intensity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: low intensive exercise
Description: Supervised walks once a week at low-intensity.
Study: NCT02766335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02358902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS - DC stimulator, Neurocom, Germany

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS - DC stimulator, Neurocom, Germany

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: active intervention of aerobic exercise
Description: different types of aerobic exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: active intervention of aerobic exercise
Description: different types of aerobic exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo tDCS
Description: only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placebo AE
Description: the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
Study: NCT05015829

Intervention type: DIAGNOSTIC_TEST
Intervention: Dobutamine Stress Echocardiography
Description: Change in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dobutamine Stress Echocardiography
Description: Change in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.
Study: NCT04964102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
Description: Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
Study: NCT03280264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: oral administration
Study: NCT02377999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picato
Study: NCT04187755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime Injection
Description: Ceftazidime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 6 hourly)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime Injection
Description: Cefepime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 8 hourly)
Study: NCT00561119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine , paclitaxel
Description: Gemcitabine 1250 mg/m2 i.v. Day 1 \& 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks
Study: NCT02733536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard endotracheal tube
Description: 1) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC
Description: C-MAC introduced with a h size 3 blade.
Study: NCT04569734

Intervention type: PROCEDURE
Intervention: WATCHMAN device implant procedure utilizing ICE probe
Description: The study will be a prospective, non-randomized multicenter registry of 100 patients undergoing LAA closure with the WATCHMAN device (possibly with WATCHMAN FLX when approved) utilizing an intra-procedural ICE probe under moderate sedation.
Study: NCT04456088

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 150 ppm Nitric Oxide delivered through LungFit Delivery System
Description: Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 80 ppm Nitric Oxide delivered through LungFit Delivery System
Description: Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.
Study: NCT03263676

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Icon resuable underwear
Description: Reusable incontinence underwear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable pad
Description: Standard market disposable pad
Study: NCT01001754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rIL-29
Description: Weekly SC injections in combination with ribavirin for up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rIL-29
Description: Weekly SC injections in combination with ribavirin for up to 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Weekly SC injections in combination with ribavirin for up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Daily oral administration (400-600 mg BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Daily oral administration (400-600 mg BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Daily oral administration (400-600 mg BID)
Study: NCT03593889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative stepped care and peer support programme
Description: For at-risk group, 4 weeks of selective prevention group sessions will be provided at the elderly service level by trained peer supporters with registered social worker supervision, on wellness topics tailored to the person's concern as entry point, packaged with mental health information, followed by a review.~For mild group, 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided. For moderate group, 6-8 weeks high-intensity cognitive behavioral therapy (CBT) would be provided. All intervention for depressed elderly would be conducted by registered social workers. The trained peer supporters will be matched to individual older adults to walk them through the process with regular follow-up for 1 year.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: The control group will receive treatment as usual, which will be determined by the responsible workers from NGO units.
Study: NCT02905604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dmPFC iTBS
Description: 2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: dmPFC Sham iTBS
Description: Sham iTBS
Study: NCT02641652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
Study: NCT01936350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
Study: NCT02321761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Description: Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
Study: NCT04054375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
Study: NCT00185224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Description: 7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH D00264A (Triquilar)
Description: 7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
Study: NCT02623582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
Description: Given IV
Study: NCT01211860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide Choline Controlled-Release Tablet
Description: DCCR 290 mg once a day for 10 days
Study: NCT02623582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT04301271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: 12 weeks 40 mg Simvastatin add-on

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 12 weeks Placebo add-on
Study: NCT03998488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery.
Study: NCT02794519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
Study: NCT03144375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical optimization and education
Description: Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care sinus surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care sinus surgery
Study: NCT04165603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Infusion of Indocyanine Green
Description: preoperatively infuse indocyanine green through peripheral vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Infusion of Indocyanine Green
Description: preoperatively infuse indocyanine green through peripheral vein

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Infusion of Indocyanine Green
Description: preoperatively infuse indocyanine green through peripheral vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Infusion of Indocyanine Green
Description: preoperatively infuse indocyanine green through peripheral vein
Study: NCT02186678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-CT
Study: NCT03494582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral Hysteropexy
Description: Abdominal approach for uterine suspension

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacrospinous Hysteropexy
Description: Transvaginal approach for uterine suspension
Study: NCT01635881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emerge™ 1.20 mm PTCA Dilatation Catheter
Description: The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.~The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures.
Study: NCT04385134

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00774800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin-R

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal
Study: NCT04260347

Intervention type: DRUG
Intervention: Alteplase
Description: Intravenous injection

Intervention type: DRUG
Intervention: Alteplase
Description: Intravenous injection
Study: NCT03023293

Intervention type: OTHER
Intervention: n-3 PUFAs consumption and irisin
Description: The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
Study: NCT00614146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARS device
Description: 10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
Study: NCT03507452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2287411
Description: Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2287411
Description: Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation.
Study: NCT03998488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium Husk Powder
Description: All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Psyllium Husk Powder
Description: All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat.
Study: NCT02681094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 5mg, orally, Green, plain, diamond-shaped, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 5mg, orally, Green, plain, diamond-shaped, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Dapagliflozin
Description: Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
Study: NCT00614146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Description: Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
Study: NCT00513942

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Movement Counting
Description: Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
Study: NCT01119092

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (laying of hands) intervention
Description: The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
Study: NCT02681094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5mg, orally, Plain, yellow, biconvex, round, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5mg, orally, Plain, yellow, biconvex, round, film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Saxagliptin
Description: Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
Study: NCT02534181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Management Protocol
Description: Strategy based on reduction of nutritional intake and electrolyte replacement.
Study: NCT01393444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of ECoG sensors on the brain surface
Description: One ECoG sensor will be implanted over the motor cortex of study participants
Study: NCT01201902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza A(H1N1) vaccine
Description: 0.25ml, Intramuscular on Day 0 and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza A(H1N1) vaccine
Description: 0.5ml, Intramuscular on Day 0 and 21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: un-adjuvanted influenza A(H1N1) vaccine
Description: 0.5ml, Intramuscular on Day 0 and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza A(H1N1) vaccine
Description: 0.25ml, Intramuscular on Day 0 and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza A(H1N1) vaccine
Description: 0.5ml, Intramuscular on Day 0 and 21
Study: NCT03302260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CardioPrevent® Program
Description: This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
Study: NCT05277597

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.
Description: Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The same exercise training program without the sauna treatments
Description: The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
Study: NCT00656136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients receive placebo once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
Study: NCT04367324

Intervention type: DEVICE
Intervention: Low-level laser therapy
Description: The low-level laser was applied to each patient in low-level laser therapy group.
Study: NCT02362295

Intervention type: OTHER
Intervention: qualitative interview
Description: some patient are interviewed.